BridgeBio Pharma Seeks Shareholder Approval for 2 Million Share Increase in Equity Incentive Plan

summarizeSummary

BridgeBio Pharma is seeking shareholder approval to add 2 million shares to its equity incentive plan, representing over 1% potential dilution, alongside other routine governance matters.

check_boxKey Events

• Equity Incentive Plan Expansion

  Shareholders will vote on increasing the shares reserved for the 2021 Stock Option and Incentive Plan by 2,000,000 shares. This represents approximately 1.03% potential dilution if all shares are issued.

• Director Elections

  Three nominees (James C. Momtazee, Frank P. McCormick, Ph.D., and Hannah A. Valantine, M.D.) are proposed for election as Class I directors.

• Executive Compensation Vote

  An advisory vote on the compensation of named executive officers is scheduled, with the Board recommending approval.

• Auditor Ratification

  Shareholders will vote to ratify Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026.

auto_awesomeAnalysis

This DEFA14A filing outlines proposals for BridgeBio Pharma's upcoming Annual Meeting, including the election of directors, advisory votes on executive compensation, and auditor ratification. The most significant proposal is the request to increase the shares reserved for the 2021 Stock Option and Incentive Plan by 2,000,000 shares. If approved and fully utilized, this would represent approximately 1.03% potential dilution to existing shareholders, providing additional equity compensation capacity for the company. While a common practice for talent retention, the magnitude of the potential dilution is notable.